Small molecule · developed by Enanta Pharmaceuticals
Zelicapavir (EDP-938) is an orally administered agent studied in respiratory syncytial virus (RSV) infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07482657 | Phase 2 | RSV Infection | Recruiting | ENTA |
| NCT05568706 | Phase 2 | RSV Infection | Completed | ENTA |
| NCT03691623 | Phase 2 | RSV Infection | Completed | ENTA |
| NCT06601192 | Phase 1 | RSV Infection | Completed | ENTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Respiratory Syncytial Virus (RSV)RSVQTc IntervalRSV Infection
Updated Oct 11, 2026. Something wrong or missing? Report it on the ENTA page.
See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ENTA catalysts and pipeline →